Immunai Inc., a New York-based artificial intelligence and biotech company specializing in mapping the human immune system, ...

Israeli-American biotech unicorn Immunai on Thursday secured a $18 million partnership to help the Anglo-Swedish pharma giant ...

While A.I. promises breakthroughs, industry leaders warn that transparency and patient safety must remain front and center.

(Reuters) - AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm’s AI model of the immune system to make certain cancer drug trials more efficient, the ...

AstraZeneca shared the topline result from the placebo-controlled trial in a press release Tuesday. NF1 affects around 1.7 million people worldwide, with about 70% being adults, according to ...

British drugmaker AstraZeneca increased its full-year sales outlook on booming demand for its cancer and rare-disease drugs, and said it plans to invest $3.5 billion in its U.S. business by the ...

LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million pounds ($576.7 million) in Britain for vaccine research and development ...

The executive in charge of AstraZeneca operations in China is under detention by Chinese authorities who are investigating employees there, the company said. The disclosure comes after AstraZeneca ...

AstraZeneca has put a £450m investment in Britain under review in a stand-off with ministers over state aid. The drugs giant told The Telegraph that proposals to build a new vaccine factory in ...

Under the terms of the agreement, AstraZeneca will leverage Immunai’s platform and machine learning capabilities to inform certain oncology clinical trials. Information ...